Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma:: a tool for comparing the efficacy of different treatment strategies and predicting outcome

被引:113
作者
San Miguel, JF
Almeida, J
Mateo, G
Bladé, J
López-Berges, C
Caballero, D
Hernández, J
Moro, MJ
Fernández-Calvo, J
Díaz-Mediavilla, J
Palomera, L
Orfao, A
机构
[1] Univ Salamanca, Hosp Clin, Serv Hematol, Salamanca 37007, Spain
[2] Ctr Invest Canc, Salamanca, Spain
[3] Univ Salamanca, Serv Citometria, E-37008 Salamanca, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Gen Hosp, Segovia, Spain
[6] Hosp Virgen Blanca, Leon, Spain
[7] Univ Valladolid, Hosp Clin, Valladolid, Spain
[8] Hosp Clin Madrid, Madrid, Spain
[9] Hosp Clin, Zaragoza, Spain
关键词
D O I
10.1182/blood.V99.5.1853
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiparametric immunophenotyping can be a sensitive method for analyzing the plasma cell (PC) compartment in patients with multiple myeloma because it discriminates between myelomatous and normal PCs. Using this approach, we compared the efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) with that of conventional chemo-therapy, We found that ASCT provided a significantly greater reduction in the level of residual tumor PCs and with better recovery of normal PCs. This profile of coexistence of normal PCs and myelomatous PCs resembled that observed in monoclonal gammopathy of undetermined significance. We also found that treatment-induced changes in the PC compartment correlated with disease outcome. Thus, patients in whom at least 30% of gated PCs had a normal phenotype after treatment had a significantly longer progression-free survival (60 +/- 6 months versus 34 +/- 12 months; P = .02).
引用
收藏
页码:1853 / 1856
页数:4
相关论文
共 14 条
[1]   High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma [J].
Almeida, J ;
Orfao, A ;
Ocqueteau, M ;
Mateo, G ;
Corral, M ;
Caballero, MD ;
Blade, J ;
Moro, MJ ;
Hernandez, J ;
San Miguel, JF .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :121-131
[2]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[3]   Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Vesole, DH ;
Naucke, S ;
Cheson, B ;
Mattox, S ;
Bracy, D ;
Salmon, S ;
Jacobson, J ;
Crowley, J ;
Tricot, G .
BLOOD, 1997, 89 (03) :789-793
[4]   High-dose therapy and innovative approaches to treatment of multiple myeloma [J].
Barlogie, B .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :21-27
[5]   ALTERNATING COMBINATION VCMP VBAP CHEMOTHERAPY VERSUS MELPHALAN PREDNISONE IN THE TREATMENT OF MULTIPLE-MYELOMA - A RANDOMIZED MULTICENTRIC STUDY OF 487 PATIENTS [J].
BLADE, J ;
SANMIGUEL, JF ;
ALCALA, A ;
MALDONADO, J ;
SANZ, MA ;
GARCIACONDE, J ;
MORO, MJ ;
ALONSO, C ;
BESALDUCH, J ;
ZUBIZARRETA, A ;
BESSES, C ;
GONZALEZBRITO, G ;
HERNANDEZMARTIN, J ;
FERNANDEZCALVO, J ;
RUBIO, D ;
ORTEGA, F ;
JIMENEZ, R ;
COLOMINAS, P ;
FAURA, MV ;
FONT, L ;
TORTOSA, J ;
DOMINGO, A ;
FONTANILLAS, M ;
ROZMAN, C ;
ESTAPE, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1165-1171
[6]  
HARADA H, 1993, BLOOD, V81, P2658
[7]  
Lenhoff S, 2000, BLOOD, V95, P7
[8]  
Ocqueteau M, 1998, AM J PATHOL, V152, P1655
[9]   Expression of the CD117 antigen (C-Kit) on normal and myelomatous plasma cells [J].
Ocqueteau, M ;
Orfao, A ;
GarciaSanz, R ;
Almeida, J ;
Gonzalez, M ;
SanMiguel, JF .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) :489-493
[10]  
ORFAO A, 2000, IMMUNOPHENOTYPING, P239